Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
APX-3330 by Ocuphire Pharma for Proliferative Diabetic Retinopathy (PDR): Likelihood of Approval
APX-3330 is under clinical development by Ocuphire Pharma and currently in Phase II for Proliferative Diabetic Retinopathy (PDR). According to...
APX-3330 by Ocuphire Pharma for Non-Proliferative Diabetic Retinopathy (NPDR): Likelihood of Approval
APX-3330 is under clinical development by Ocuphire Pharma and currently in Phase II for Non-Proliferative Diabetic Retinopathy (NPDR). According to...
APX-3330 by Apexian Pharmaceuticals for Endometrial Cancer: Likelihood of Approval
APX-3330 is under clinical development by Apexian Pharmaceuticals and currently in Phase I for Endometrial Cancer. According to GlobalData, Phase...
APX-3330 by Apexian Pharmaceuticals for Hepatocellular Carcinoma: Likelihood of Approval
APX-3330 is under clinical development by Apexian Pharmaceuticals and currently in Phase I for Hepatocellular Carcinoma. According to GlobalData, Phase...
APX-3330 by Apexian Pharmaceuticals for Bladder Cancer: Likelihood of Approval
APX-3330 is under clinical development by Apexian Pharmaceuticals and currently in Phase I for Bladder Cancer. According to GlobalData, Phase...
APX-3330 by Apexian Pharmaceuticals for Melanoma: Likelihood of Approval
APX-3330 is under clinical development by Apexian Pharmaceuticals and currently in Phase I for Melanoma. According to GlobalData, Phase I...
APX-3330 by Apexian Pharmaceuticals for Colorectal Cancer: Likelihood of Approval
APX-3330 is under clinical development by Apexian Pharmaceuticals and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase...
APX-3330 by Apexian Pharmaceuticals for Prostate Cancer: Likelihood of Approval
APX-3330 is under clinical development by Apexian Pharmaceuticals and currently in Phase I for Prostate Cancer. According to GlobalData, Phase...
APX-3330 by Apexian Pharmaceuticals for Ovarian Cancer: Likelihood of Approval
APX-3330 is under clinical development by Apexian Pharmaceuticals and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase...
APX-3330 by Apexian Pharmaceuticals for Solid Tumor: Likelihood of Approval
APX-3330 is under clinical development by Apexian Pharmaceuticals and currently in Phase I for Solid Tumor. According to GlobalData, Phase...